Inhalable drug given green light

News

Author: Simge Eva DoganPublished: 9 January 2019

Parkinson's LifePrep: Parkinson's LifeCook: Parkinson's LifeServes:

levodopa

The US Food and Drug Administration (FDA) has approved INBRIJA – an inhalable drug created by US biotech company Acorda Therapeutics – for intermittent treatment.

INBRIJA is designed to treat Parkinson’s symptoms that occur between oral doses of medication, which are known as ‘off’ episodes. The drug has been approved by the FDA and – after a clinical study involving 900 people with Parkinson’s – is expected to be available in 2019.

Todd Sherer, CEO of The Michael J Fox Foundation, who funded early trials of the powder, said: “Despite being on treatment, patients may experience OFF periods as Parkinson’s progresses, which can be disruptive.

“We knew we had to help address this unmet need, and this approval is a significant step forward for the community as it provides a new option to manage these gaps in symptom control.”

To read more on this topic click here.

For more information on Parkinson’s medication please visit the EPDA website.


Read more:

Researchers create Parkinson’s-resistant stem cells

Memory loss could be an indication of Parkinson’s

Go Back

Share this story

Comments


Related articles


Sharon Krischer lead image

Perspectives

World Parkinson Congress 2019 Bloggers: Sharon Krischer

#WPC2019: We talk to American blogger Sharon Krischer

READ MORE

Resources & Tools

An end to writer’s block for people with Parkinson’s?

New pen developed to improve handwriting for Parkinson's patients

READ MORE

Europe

High-profile MEP supports European inventory research initiative

EPDA launches new My PD Journey research project

READ MORE